# Endocannabinoid Activity Remodulation for Psychosis Liability in Youth

> **NCT06037993** · NA · UNKNOWN · sponsor: **University of Udine** · enrollment: 20 (estimated)

## Conditions studied

- Clinical High Risk for Psychosis
- Ultra High Risk for Psychosis
- Attenuated Psychotic Symptoms

## Interventions

- **DIETARY_SUPPLEMENT:** Ultra-micronized Palmitoylethanolamide (PEA)

## Key facts

- **NCT ID:** NCT06037993
- **Lead sponsor:** University of Udine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2024-11
- **Final completion:** 2025-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037993, "Endocannabinoid Activity Remodulation for Psychosis Liability in Youth". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06037993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*